ID: ALA2063396

Max Phase: Preclinical

Molecular Formula: C29H44N6O4

Molecular Weight: 540.71

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCC[C@@H]1NC(=O)[C@H](C)NC(=O)C[C@H](CC(C)C)NC(=O)[C@H](Cc2cn(CN(C)C)c3ccccc23)NC1=O

Standard InChI:  InChI=1S/C29H44N6O4/c1-7-10-23-28(38)33-24(14-20-16-35(17-34(5)6)25-12-9-8-11-22(20)25)29(39)31-21(13-18(2)3)15-26(36)30-19(4)27(37)32-23/h8-9,11-12,16,18-19,21,23-24H,7,10,13-15,17H2,1-6H3,(H,30,36)(H,31,39)(H,32,37)(H,33,38)/t19-,21-,23-,24-/m0/s1

Standard InChI Key:  OEZSNGIQMOKVLE-OHCFRWENSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 540.71

Molecular Weight (Monoisotopic): 540.3424

AlogP: 1.91

#Rotatable Bonds: 8

Polar Surface Area: 124.57

Molecular Species: BASE

HBA: 6

HBD: 4

#RO5 Violations: 1

HBA (Lipinski): 10

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 11.07

CX Basic pKa: 8.94

CX LogP: 2.27

CX LogD: 0.72

Aromatic Rings: 2

Heavy Atoms: 39

QED Weighted: 0.41

Np Likeness Score: 0.64

References

1. Vickers CJ, Olsen CA, Leman LJ, Ghadiri MR..  (2012)  Discovery of HDAC Inhibitors That Lack an Active Site Zn(2+)-Binding Functional Group.,  3  (6): [PMID:24900500] [10.1021/ml300081u]

2. Lai JI, Leman LJ, Ku S, Vickers CJ, Olsen CA, Montero A, Ghadiri MR, Gottesfeld JM..  (2017)  Cyclic tetrapeptide HDAC inhibitors as potential therapeutics for spinal muscular atrophy: Screening with iPSC-derived neuronal cells.,  27  (15): [PMID:28648462] [10.1016/j.bmcl.2017.06.027]

Source

Source(1):

• Scientific Literature